Effect of VIVO(dipic-Cl)‎(H2O)‎2 on Lipid Metabolism Disorders in the Liver of STZ-Induced Diabetic Rats

Abstract EN

Vanadium complexes are potent antidiabetic agents for therapeutical treatment of diabetes.

In the present study, we investigated the hypolipidemic effect of VIVO(dipic-Cl)(H2O)2 (V4dipic-Cl) in liver of streptozotocin- (STZ-)-induced diabetic rats.

We found that diabetic animals exhibited hepatic inflammatory infiltration and impaired liver function along with triglyceride (TG) accumulation in the liver.

V4dipic-Cl treatment not only ameliorated liver pathological state but also reduced hepatic TG level.

Moreover, the upregulation of fatty acid translocase (FAT/CD36) mRNA (4.0-fold) and protein (8.2-fold) levels in the liver of diabetic rats were significantly reversed after V4dipic-Cl treatment.

However, no significant effects of V4dipic-Cl on the mRNA expression of fatty acid metabolism-related fatty acid bounding protein 1 (FABP1) and fatty acid transporter 5 (FATP5) were observed.

These results suggest that the modification of lipid metabolism-related FAT/CD36 in the liver of diabetic rats is likely involved in the hypolipidemic effects of V4dipic-Cl.